dsp 4 has been researched along with physostigmine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, KL; Haroutunian, V; Santucci, AC | 1 |
| Itoh, Y; Kimura, K; Ogasawara, T; Tamura, M; Ukai, Y; Yoshikuni, Y | 1 |
| Nuñez, A; Reyes-Marin, KE | 1 |
3 other study(ies) available for dsp 4 and physostigmine
| Article | Year |
|---|---|
Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Benzylamines; Cholinergic Agents; Cholinergic Fibers; Clonidine; Disease Models, Animal; Male; Memory; Organic Chemicals; Oxotremorine; Parasympathomimetics; Physostigmine; Rats; Rats, Inbred Strains; Substantia Innominata | 1991 |
NS-3, a TRH-analog, reverses memory disruption by stimulating cholinergic and noradrenergic systems.
Topics: Acetylcholine; Animals; Avoidance Learning; Basal Ganglia; Benzylamines; Biogenic Monoamines; Choline; Dose-Response Relationship, Drug; Male; Memory; Norepinephrine; Parasympathomimetics; Physostigmine; Rats; Rats, Wistar; Sodium; Sympathomimetics; Thyrotropin-Releasing Hormone | 1996 |
Seizure susceptibility in the APP/PS1 mouse model of Alzheimer's disease and relationship with amyloid β plaques.
Topics: Alzheimer Disease; Animals; Benzylamines; Cerebral Cortex; Disease Models, Animal; Disease Susceptibility; Electrocorticography; Female; Male; Mice, Inbred C57BL; Mice, Transgenic; Pentylenetetrazole; Physostigmine; Plaque, Amyloid; Seizures | 2017 |